Exactly my take on it psych, FDA trial lift for AML & Ovarian cannot get any more subtle in that the data reviewed by the FDA is as expected with regard to efficacy & toxicity/safety not an SAE contributing factor.
Looking forward to the AML 1B second cohort to complete enrolement & dosing. Given AML is a very rapid disease we should not be waiting too much longer before trial data is released, possibly by years end / very early 2018...IMO. From there on it's PTX time to shine!
PTX Price at posting:
6.7¢ Sentiment: Buy Disclosure: Held
